Accessibility setting


Select language

Skip to secondary menu

Skip to content

Jehovah’s Witnesses


Intensive and Critical Care

Anemia Management

Severe acute anemia after liver transplantation in an elderly Jehovah's Witness treated with high-dose erythropoietin and ferric carboxymaltose: a case report.

Brunetta DM, Kaufman J, De Santis GC, Mesquita DF, Souza FN, Garcia JH

Source‎: Transplant Proc 2015;47(8):2548-51.

Indexed‎: PubMed 26518969

DOI‎: 10.1016/j.transproceed.2015.09.014

Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial.

Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ.

Source‎: Crit Care Med 1999;27(11):2346-50.

Indexed‎: PubMed 10579246

Long-term ECMO treatment in Jehovah’s Witness patient without transfusions.

Lindholm J, Palmér K, Frenckner B.

Source‎: Perfusion 2012;27(4):332-4.

Indexed‎: PubMed 22496111

DOI‎: 10.1177/0267659112444328

Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study.

Talving P, Lustenberger T, Inaba K, Lam L, Mohseni S, Chan L, Demetriades D.

Source‎: Arch Surg 2012;147(3):251-5.

Indexed‎: PubMed 22430906

DOI‎: 10.1001/archsurg.2011.1838

Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses.

Ball AM, Winstead PS.

Source‎: Pharmacotherapy 2008;28(11):1383-90.

Indexed‎: PubMed 18956998

DOI‎: 10.1592/phco.28.11.1383

Improved survival of critically ill trauma patients treated with recombinant human erythropoietin.

Napolitano LM, Fabian TC, Kelly KM, Bailey JA, Block EF, Langholff W, Enny C, Corwin HL.

Source‎: J Trauma 2008;65(2):285-97.

Indexed‎: PubMed 18695463

DOI‎: 10.1097/TA.0b013e31817f2c6e

Recombinant human erythropoietin in severe anaemia: issues of dosing and duration.

Charles A, Purtill M, Napolitano LM.

Source‎: Anaesth Intensive Care 2006;34(6):793-6.

Indexed‎: PubMed 17183900

Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317].

Georgopoulos D, Matamis D, Routsi C, Michalopoulos A, Maggina N, Dimopoulos G, Zakynthinos E, Nakos G, Thomopoulos G, Mandragos K, Maniatis A; Critical Care Clinical Trials Greek Group.

Source‎: Crit Care 2005;9(5):R508-15.

Indexed‎: PubMed 16277712

Recombinant human erythropoietin use in a critically ill Jehovah's Witness after cardiac surgery.

Price S, Pepper JR, Jaggar SI.

Source‎: Anesth Analg 2005;101(2):325-7.

Indexed‎: PubMed 16037136

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.